活血潜阳祛痰方治疗原发性高血压的随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验纳入216例1-2级高血压伴血瘀、阳亢或痰湿证患者,在常规降压治疗基础上加用活血潜阳祛痰方(HQQR)颗粒或安慰剂12周。结果显示HQQR组诊室及家庭血压、HOMA-IR、TC、UACR、hs-CRP和IL-6均显著改善(P<0.001),且未报告副作用。
要点
- HQQR联合常规降压可进一步降低诊室和家庭血压。
- HQQR可改善胰岛素抵抗、血脂、UACR及炎症指标。
- 试验中未报告HQQR相关副作用。
核心结论
- HQQR可改善高血压患者的血压、糖脂代谢和炎症状态。
研究设计与样本
- 随机双盲安慰剂对照试验,于2020年7月至2022年6月在岳阳医院开展,共纳入216例18-80岁1-2级高血压伴血瘀、阳亢或痰湿证患者,每组108例,疗程12周。
主要发现
- 干预组诊室收缩压(136.24±7.63 vs 130.06±8.50 mmHg)和舒张压(84.34±8.72 vs 80.46±6.05 mmHg)均显著优于对照组(P<0.001)。
- 干预组家庭收缩压(131.64±8.74 vs 122.36±8.45 mmHg)和舒张压(78.47±9.53 vs 71.79±6.82 mmHg)均显著优于对照组(P<0.001)。
- HQQR降低24小时收缩压(133.75±10.49 vs 132.46±8.84 mmHg)和舒张压(84.12±8.01 vs 82.11±7.45 mmHg),并改善HOMA-IR(4.09±1.72 vs 3.98±1.44)、TC(4.66±1.47 vs 3.75±1.81 mmol/L)和UACR(75.94 [5.12, 401.12] vs 45.61 [4.26, 234.26])。
- HQQR降低hs-CRP(1.46 [0.10, 10.53] vs 0.57 [0.12, 3.99] mg/L)和IL-6(6.69 [2.00, 29.74] vs 5.27 [2.00, 9.73] pg/mL),未报告副作用(P<0.001)。
关键数值与推荐
- HQQR主要成分经薄层色谱和高效液相色谱鉴定为丹酚酸B、大黄素和阿魏酸。
临床怎么用
- 对于1-2级高血压伴血瘀、阳亢或痰湿证患者,可在常规降压治疗基础上考虑加用HQQR颗粒以辅助改善血压、糖脂代谢及炎症指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension, a prevalent disease, is a significant risk factor for coronary heart disease. Huoxue Qianyang Qutan Recipe (HQQR), a traditional Chinese herbal remedy, has been used for treating hypertension over several years. OBJECTIVE: This study assesses HQQR's efficacy for controlling blood pressure among patients with hypertension related to blood stasis, yang hyperactivity and phlegm. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A randomized controlled trial was conducted at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, China, from July 2020 to June 2022. Major components of HQQR were identified using thin-layer chromatography and high-performance liquid chromatography. Participants aged 18-80 years, exhibiting traditional Chinese medicine syndromes of blood stasis, yang hyperactivity or phlegm, along with grades 1 or 2 hypertension, were randomly categorized into two groups. The intervention group was given HQQR granules alongside conventional hypertension treatment, while the control group was given placebo granules in addition to conventional treatment for 12 weeks. MAIN OUTCOME MEASURES: The primary outcome was clinic blood pressure, whereas secondary outcomes included metabolic indices (e.g., homeostasis model assessment of insulin resistance [HOMA-IR], total cholesterol [TC], low-density lipoprotein cholesterol and triglyceride), target organ damage indices (left ventricular mass index and urinary albumin creatinine ratio [UACR]) and inflammation indices (interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hs-CRP]). RESULTS: HQQR's primary components were identified as salvianolic acid B, emodin and ferulic acid. Of the 216 participants (108 in each group), compared to the control, the intervention group exhibited significant improvements (P < 0.001) in clinic systolic blood pressure ([136.24 ± 7.63] vs [130.06 ± 8.50] mmHg), clinic diastolic blood pressure ([84.34 ± 8.72] vs [80.46 ± 6.05] mmHg), home systolic blood pressure ([131.64 ± 8.74] vs [122.36 ± 8.45] mmHg) and home diastolic blood pressure ([78.47 ± 9.53] vs [71.79 ± 6.82] mmHg). HQQR demonstrated a reduction in ambulatory blood pressure (24-hour systolic blood pressure: [133.75 ± 10.49] vs [132.46 ± 8.84] mmHg and 24-hour diastolic blood pressure: [84.12 ± 8.01] vs [82.11 ± 7.45] mmHg) and an improvement in HOMA-IR ([4.09 ± 1.72] vs [3.98 ± 1.44]), TC ([4.66 ± 1.47] vs [3.75 ± 1.81] mmol/L) and UACR (75.94 [5.12, 401.12] vs 45.61 [4.26, 234.26]). Moreover, HQQR demonstrated a decrease in hs-CRP (1.46 [0.10, 10.53] vs 0.57 [0.12, 3.99] mg/L) and IL-6 (6.69 [2.00, 29.74] vs 5.27 [2.00, 9.73] pg/mL), with no reported side effects (P < 0.001). CONCLUSION: This study highlights the therapeutic potential of HQQR use in ameliorating blood pressure, glycolipid metabolism, and inflammation in patients with hypertension. TRIAL REGISTRATION: ChiCTR2000035092 (https://www.chictr.org.cn/). Please cite this article as: Xie J, Ma YL, Gui MT, Yao L, Li JH, Wang MZ, Zhou XJ, Wang YF, Zhao MY, Cao H, Lu B, Fu DY. Efficacy of Huoxue Qianyang Qutan Recipe on essential hypertension: A randomized, double-blind, placebo-controlled trial. J Integr Med 2024; 22(4): 485-493.
引用
- Xie J, Ma YL, Gui MT, et al. Efficacy of Huoxue Qianyang Qutan Recipe on essential hypertension: A randomized, double-blind, placebo-controlled trial. J Integr Med. 2024. PMID: 38789290. doi:10.1016/j.joim.2024.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。